Prism adaptation induces rapid recalibration of visuomotor coordination. The neural mechanisms of prism adaptation have come under scrutiny since the observations that the technique can alleviate hemispatial neglect following stroke, and can alter spatial cognition in healthy controls. Relative to non-imaging behavioral studies, fMRI investigations of prism adaptation face several challenges arising from the confined physical environment of the scanner and the supine position of the participants. Any researcher who wishes to administer prism adaptation in an fMRI environment must adjust their procedures enough to enable the experiment to be performed, but not so much that the behavioral task departs too much from true prism adaptation. Furthermore, the specific temporal dynamics of behavioral components of prism adaptation present additional challenges for measuring their neural correlates. We developed a system for measuring the key features of prism adaptation behavior within an fMRI environment. To validate our configuration, we present behavioral (pointing) and head movement data from 11 right-hemisphere lesioned patients and 17 older controls who underwent sham and real prism adaptation in an MRI scanner. Most participants could adapt to prismatic displacement with minimal head movements, and the procedure was well tolerated. We propose recommendations for fMRI studies of prism adaptation based on the design-specific constraints and our results.

Download full-text PDF

Source
http://dx.doi.org/10.3758/s13428-016-0840-zDOI Listing

Publication Analysis

Top Keywords

prism adaptation
40
prism
10
adaptation
10
adaptation fmri
8
fmri environment
8
fmri
5
studying neural
4
neural bases
4
bases prism
4
fmri technical
4

Similar Publications

Background Underutilization of medications for opioid use disorder (MOUD), which reflects the limited number of patients initiating treatment and being retained in treatment, remains a persistent barrier to addressing the opioid epidemic. Using an adapted PRISM (Practical, Robust Implementation and Sustainability Model) framework, this study describes multi-level barriers and facilitators to expanding MOUD as part of the HEALing (Helping to End Addiction Long-term®) Communities Study in Kentucky (HCS-KY). Methods Cross-sectional small group and individual semi-structured interviews were conducted with 60 employees representing 30 MOUD agencies in eight Kentucky counties from December 2022 to June 2023.

View Article and Find Full Text PDF

Protocol for generating a co-culture of macrophages with breast cancer tumoroids.

STAR Protoc

December 2024

University Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, F-59000 Lille, France; Equipe Labellisée Ligue Contre le Cancer, Lille, France. Electronic address:

Cancer progression and treatment outcomes are heavily influenced by the tumor microenvironment (TME), especially through immune cell interactions. Here, we present a protocol for generating co-cultures of tumoroids with macrophages, either semi-liquid or Matrigel-embedded. We describe steps for macrophage preparation, co-culture establishment, and medium adjustments to support cell viability and function.

View Article and Find Full Text PDF

Background Aplastic anemia (AA) is a rare and heterogeneous hematological disorder defined as pancytopenia with hypocellular bone marrow in the absence of abnormal infiltration or medullary fibrosis. Various causes of AA have been identified, such as autoimmune factors, bone marrow injuries, viral infections, and genetic disorders. The symptoms of AA are directly linked to pancytopenia and the most common are fatigue, recurrent infections, and bleeding problems.

View Article and Find Full Text PDF

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.

Clin Pharmacol Ther

November 2024

Laboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire, UR7296, Hopitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.

Mavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility.

View Article and Find Full Text PDF

Implementation science theories, models, and frameworks (TMF) should help users understand complex issues in translating research into practice, guide selection of appropriate implementation strategies, and evaluate implementation outcomes. They should also be sensitive to evidence from projects that apply the framework, evolve based on those experiences, and be accessible to a range of users. This paper describes these issues as they relate to the Practical, Robust Implementation and Sustainability Model (PRISM).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!